Back to Authors

Hollant, Laeticia

Mayo Clinic

Mayo Clinic in Florida

Citations 11

Assessing distress in patients with gastrointestinal tumors during radiotherapy.
Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Smart, Bridget, Habboush, Jacob, Kaleem, Tasneem , Tzou, Katherine S., Ko, Stephen, Biers, Heather, Day, Atiya, May, Byron C. , Miller, Robert C.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18087-e18087

10.1200/jco.2016.34.15_suppl.e18087 Get It

Patient reported distress in head and neck cancer patients receiving radiotherapy.
Gaines, Katherine , Hollant, Laeticia, Smart, Bridget, Single, Megan Paige, Habboush, Jacob, Tzou, Katherine S., Biers, Heather, Day, Atiya, Wert, K. , May, Byron C. , Ko, Stephen J. , Miller, Robert C.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18086-e18086

10.1200/jco.2016.34.15_suppl.e18086 Get It

Patient reported distress symptoms in patients undergoing palliative radiotherapy.
Single, Megan Paige, Hollant, Laeticia, Gaines, Katherine , Smart, Bridget, Habboush, Jacob, Biers, Heather, Day, Atiya, Vallow, Laura A., Tzou, Katherine S., May, Byron C. , Miller, Robert C.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18085-e18085

10.1200/jco.2016.34.15_suppl.e18085 Get It

Patient reported distress and survival after palliative radiotherapy.
Habboush, Jacob, Shannon, Robert P. , Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Smart, Bridget, Buskirk, Steven J., Vallow, Laura A., Tzou, Katherine S., Peterson, Jennifer , Biers, Heather, Day, Atiya, May, Byron C. , Ko, Stephen J. , Miller, Robert C.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18084-e18084

10.1200/jco.2016.34.15_suppl.e18084 Get It

Patient-reported distress screening outcomes in breast cancer.
Smart, Bridget, Vallow, Laura A., Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Habboush, Jacob, Biers, Heather, Day, Atiya, Tzou, Katherine S., May, Byron C. , Miller, Robert C.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e18083-e18083

10.1200/jco.2016.34.15_suppl.e18083 Get It

Patient reported distress is predictive of survival in patients with gastrointestinal tumors.
Whitaker, D., Hintenlang, Lauren L., Jagadsh, Niveditha, Strong, Gerald, Buskirk, Steven J., Peterson, Jennifer , Tzou, Katherine S., Vallow, Laura A., May, Byron C. , Habboush, Jacob, Hollant, Laeticia, Ko, Stephen J. , Miller, Robert C.

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 764-764

10.1200/jco.2017.35.4_suppl.764 Get It

764 Background: Psychosocial distress screening and assessment in patients with gastrointestinal (GI) cancers has an established importance due to the distress experienced during and post treatment. GI cancer patients receiving radiotherapy (RT) for curative or palliative measures were reviewed in order to determine if there was a relationship between patient reported distress (PRD) and survival. Methods: Patients at our institution who receive external beam RT for GI cancers completed a 30 question PRD survey that also included a linear analog measure of overall distress, the National Comprehensive Cancer Network (NCCN) Distress Thermometer, which ranged from 1 (low overall distress) to 10 (high overall stress) at the start of and/or during treatment. Each question on the PRD questionnaire concentrated on a possible cause of distress. It allowed patients to rate distress levels for each question from 1 to 5 (1 being the least distressed and 5 being the most distressed), and also overall distress according. The reported clinical results of the PRD questionnaire were retrospectively reviewed in patients receiving RT for GI cancers from Jan 2012 to Aug 2015. Patients were considered distressed if their overall PRD score was 5 or greater (PRD+) or not distressed (PRD-) if their score was 4 or under. Overall survival between PRD+ and PRD- was compared using the Kaplan-Meier method. Results: PRD surveys were completed by 134 consecutive patients, 67 (50%) male and 67 (50%) female within 30 days of starting RT. The median age was 65 years (range 28 to 93). The top histological finding was adenocarcinoma, 90 patients (60%). 113 (84%) received chemotherapy and 64 (48%) underwent surgery. 102 (75%) treatments were curative and 32 (25%) were palliative. Overall NCCN distress thermometer results ranged from 0 to 10, with a median of 4. Median follow-up was 2.7 years. Distressed patients (PRD+) had inferior survival to those not distressed (PRD-) at 2 years, 52% vs. 72%, p<0.02. Conclusions: Patient reported distress is associated with an inferior survival in patients receiving radiotherapy for gastrointestinal tumors.
Assessing distress in patients with gastrointestinal tumors during radiotherapy.
Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Smart, Bridget, Habboush, Jacob, Kaleem, Tasneem , Tzou, Katherine S., Biers, Heather, Day, Atiya, Ko, Stephen J. , Miller, Robert C.

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 4_suppl | Pages: 524-524

10.1200/jco.2016.34.4_suppl.524 Get It

524 Background: Psychosocial distress during radiotherapy (RT) for gastrointestinal tumors is poorly characterized. Since 2012, patients receiving RT in our clinic have been prospectively screened for causes of distress. The results of our screening were reviewed in order to elucidate concerns of GI cancer patients and to delineate patterns within patient reported distress (PRD). Methods: Patients treated with RT at our institution receive a 30 question PRD survey that also includes a linear analog measure of overall distress at the start and during RT. The PRD survey asks patients to rate forms of distress on a scale of 1 to 5 (5 being the most distressed). The survey also asks patients to rate overall distress according to the National Comprehensive Cancer Network (NCCN) Distress Thermometer on a scale 0 to 10. The reported results were retrospectively reviewed in patients receiving definitive RT for GI cancers from 04/02/2012 to 08/05/2015. Results: PRD surveys were completed by 113 patients, 55 (48.7%) male and 58 (51.3%) female. Median age was 65 years (range 28 to 93). The most common tumor histology was adenocarcinoma, 67 (59.3%). 105 patients (93.0%) received chemotherapy and 66 (58.4%) underwent surgery. Overall, NCCN distress thermometer results ranged from 0 to 10, with a median of 4.3. The mean distress scores for the top five complaints ranged from 1.27 to 2.63. Top distresses were “How will I feel during treatment” (2.63), “Fatigue” (2.45), “Pain that affects daily functioning” (2.35), “Out of pocket medical costs” (2.31), and “Sleep difficulties” (2.31). The least concerning complaints were “Housing during treatment” (1.27), “A loved one relying on me for their physical care” (1.30), “Spirituality” (1.33),“Family communication about my illness”(1.37), and “Transportation” (1.38). Conclusions: Patients’ major concerns were aligned with daily quality of life, such as fatigue, pain and insomnia. Highest reported distress was linked with the process of RT and side effects associated with treatment. Medical expenses were also perceived as a burden. Medical providers should identify psychosocial stressors during RT in order to effectively communicate and provide resources to improve quality of life.
Patient-reported distress symptoms in patients undergoing palliative radiotherapy.
Single, Megan Paige, Hollant, Laeticia, Gaines, Katherine , Smart, Bridget, Habboush, Jacob, Biers, Heather, Day, Atiya, Vallow, Laura A., Tzou, Katherine S., Miller, Robert C.

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 29_suppl | Pages: 75-75

10.1200/jco.2015.33.29_suppl.75 Get It

75 Background: The focus of palliative radiotherapy (RT) is on improving quality of life (QOL) for patients with serious illnesses by eliminating or decreasing physical symptoms. The importance of assessing distress levels in palliative care patients is recognized due to the relevance of QOL, as treatment is given to provide symptom-relief rather than curative results. We sought to identify the most common causes of patient reported distress during palliative RT. Methods: Retrospective review was performed for patients who received palliative RT from 11/1/2012 to 6/4/2015 for various types of metastatic cancer at our institution. All patients completed a Patient Reported Distress (PRD) questionnaire with 30 specific questions and an overall distress thermometer prior to beginning treatment. The PRD survey quantified 30 areas of current concern ranging in patient-reported values from 1 to 5 in addition to a linear analog measure from 0 to 10 of overall reported distress in the last month. Results: Completed PRD surveys were available for a total of 297 patients, 149 (50.2%) female and 148 (49.8%) male. All patients were undergoing external beam radiation therapy for treatment of metastatic disease. 49 (16%) received chemotherapy and 46 (9%) underwent surgery. Overall distress ranged from 0 to 10, with a median of 5.0. The mean distress scores for the top five concerns ranged from 1.4 to 2.7. Top distresses were “Fatigue” (2.7), “Pain that affects daily functioning” (2.6), “How will I feel during treatment” (2.5), “Sleep difficulties” (2.4), and “Out of pocket medical costs” (2.3). Least troubling symptoms were “Transportation” (1.4), “A loved one relying on me for their physical care” (1.5), “My job” (1.5), “Housing during treatment” (1.5), “Spirituality” (1.5), and “Anger” (1.5). Conclusions: Patients demonstrated concern for distress related to interruption of activities of normal life, such as tiredness and insomnia, pain, and overall burdens from treatment. Medical costs were also a major concern. Importantly, housing and transportation were not issues in the current study but could be of concern in other regions. Providers should be aware that patients’ primary concerns may not be directly related to the symptom being palliated.
Patient distress and survival in palliative radiotherapy.
Habboush, Jacob, Shannon, Robert P. , Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Smart, Bridget, Buskirk, Steven J., Vallow, Laura A., Tzou, Katherine S., Peterson, Jennifer , Biers, Heather, Day, Atiya, Ko, Stephen J. , Miller, Robert C.

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 3_suppl | Pages: 211-211

10.1200/jco.2016.34.3_suppl.211 Get It

211 Background: Distress is known to be elevated in patients receiving cancer therapy, such as palliative radiotherapy (PRT). Many patients will experience distress during treatment and it is not always addressed in part due to a lack of guidance regarding the significance of distress. Methods: All RT patients in our clinic are asked to complete a patient reported distress (PRD) survey during treatment course. PRD forms consist of 30 categorical questions that assess distress subscales. Patients have the option to rate each question from 1 (low distress) to 5 (high distress). The survey also includes the National Comprehensive Cancer Network distress thermometer, which allows patients to rate overall distress level from 0 (no distress) to 10 (extreme distress). Patients’ records were retrospectively reviewed to abstract the needed information to assess survivorship. Results: 270 patients were included from 01/18/2012-08/07/2015. Overall PRD was analyzed as a continuous and a categorical variable (low: 0-3, moderate: 4-6, high: 7-10). Continuous and categorical variable PRD did not show a correlation of distress to survival (P = 0.26) and (P = 0.10) respectively. A correlation was noted in moderate distress category (RR: 1.51, P = 0.034), however, this was not noted in high distress category (RR: 1.25, P = 0.33). There was no statistical significant correlation with the adjusted variables. Patients with primary site of gastrointestinal cancer had worst prognosis (RR: 1.34, P: 0.14), while hematological origin had best prognosis (RR: 0.35, P: 0.038).Age had the strongest correlation with survival, as older patients receiving RT had poorer survival (RR: 1.13, P: 0.079). Conclusions: This study suggests that PRD is not predictive of survival in PRT. The primary goal of PRT is to improve quality of life (QoL) by assessing, anticipating and alleviating suffering; not necessarily improve survival. It also demonstrated that the most common stressors were related to reversible short-term side effects of RT such as fatigue and pain rather than long-term stressors related to daily activities and social measures which might affect QoL. It is imperative to explore assessment tools to mitigate suffering and improve strategies to enhance QoL in all medical disciplines.
Patient-reported distress screening outcomes in breast cancer.
Smart, Bridget, Vallow, Laura A., Hollant, Laeticia, Single, Megan Paige, Gaines, Katherine , Habboush, Jacob, Biers, Heather, Day, Atiya, Tzou, Katherine S., Miller, Robert C.

Journal of Clinical Oncology | February 24, 2017 | Volume: 33 | Issue: 28_suppl | Pages: 79-79

10.1200/jco.2015.33.28_suppl.79 Get It

79 Background: A significant percentage of cancer patients experience psychosocial distress with the highest prevalence observed in breast cancer patients. The importance of psychosocial distress screening and assessment in women with breast cancer has clearly been established. Patients in our clinic are screened for distress. The results were reviewed in an attempt to better understand the psychosocial distress of breast cancer patients undergoing radiotherapy. Methods: Patients treated curatively for breast cancer prospectively completed the 30 question patient reported distress (PRD) survey that also included a linear analog measure of overall distress. The recorded clinical results of the PRD survey were retrospectively assessed in patients receiving breast radiotherapy from June 1, 2013 to February 2, 2015. Results: Completed PRD questionnaires were available on 179 female patients. 21 (12%) were treated for ductal carcinoma in situ and 91 (51%), 35 (20%), and 32 (18%) were treated for invasive carcinoma Stages I, II, and III. 85 (47%) received chemotherapy. Overall distress ranged from 0 to 10, with a median value of 5. Mean distress scores per category ranged from a low of 1.25 to a high of 2.52. Top concerns in descending order of importance were: “How will I feel during treatment” (2.52), “Fatigue” (2.46), “Sleep difficulties” (2.32), “How will I feel about appearance related to treatment” (2.23), & “Pain that affects daily functioning” (2.19). Least distressing symptoms “Spirituality” (1.25), “Housing during treatment” (1.26), “Control of anger” (1.28), “End of life concerns” (1.32), & “Transportation” (1.34). Conclusions: Distress over tumor related issues ranked low among women’s concerns in comparison to distress related to the side effects of therapy concerning treatment related discomfort, fatigue, and changes in appearance, and anxiety. Pain was a significant concern, although in this group of patients receiving definitive, adjuvant or neoadjuvant therapy, this was likely related to treatment associated discomfort rather than from disease progression. These findings highlight the importance of careful patient education and communication of the expected symptoms and effects of therapy.